Activated platelets express P-selectin and release leukocyte chemoattractants; however, they have not been known to express integrin ligands important in the stabilization of leukocyte interactions with the vasculature. We now demonstrate the presence of intercellular adhesion molecule-2 (ICAM-2) (CD102), and lack of expression of other P2-integrin ligands, ICAM-1 (CD54) and ICAM-3 (CD50), on the surface of resting and stimulated platelets. ICAM-2 isolated from platelets migrates as a band of 59,000 Mr in reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Staining of bone marrow aspirates with anti-ICAM-2 mAb demonstrates strong reactivity to megakaryocytes. Using frozen thin sections and immunogold labeling, the antigen was shown to be present on the plasma membrane and surface-connected canalicular system of resting platelets. The average number of ICAM-2 molecules per platelet is 3,000±230 and does not change after activation. In adhesion assays, resting and stimulated platelets were capable of binding through ICAM-2 to purified leukocyte function-associated antigen-i. Activation of T lymphocytes with PMA stimulated binding to platelets that was Mg2+ dependent and could be specifically inhibited by mAbs to either ICAM-2 or leukocyte function-associated antigen-i.
Introduction
Platelets play a central role in hemostasis involving complex interactions among these cells, leukocytes, and the injured vessel wall. Adhesion of platelets to exposed subendothelium requires the concerted actions of extracellular matrix components, the integrin family of adhesion receptors, and glycoprotein Ib (1, 2) . These molecules, in conjunction with the contents of alpha granules and dense granules released during platelet acti-primarily involved in platelet-leukocyte interactions.
The recruitment of leukocytes from the blood, essential for inflammation and the immune response, is an active process requiring at least three sequential events. The initial interaction (step 1) is mediated by the selectin family of molecules and their oligosaccharide ligands, an event that is both transient and reversible. Subsequent stabilization of leukocyte-endothelial interactions requires both the activation of leukocyte adhesion molecules by specific chemoattractants (step 2) and binding of integrins on leukocytes to counterreceptors on the vascular wall (step 3). Participants in the first two of these steps have been defined on platelets. P-selectin, an integral membrane protein translocated to the surface of activated platelets (5, 6) , has been shown to interact specifically with leukocytes under flow conditions (7, 8) . Platelets also release several leukocyte chemoattractants after activation, including RANTES, and platelet basic protein that is converted to neutrophil activating peptide-2 (9, 10). The presence of an integrin ligand, important in the third step of the adhesion process, has not been identified on platelets. CD3 1, a member of the immunoglobulin superfamily that is expressed on platelets, leukocytes, and endothelium, has been suggested as a possible candidate, but has not been demonstrated to mediate platelet-leukocyte adhesion (11) . Another study has provided evidence for recognition by /32-integrins of a counter-structure on platelets that appears to be involved in adhesion (12) .
Understanding the different steps involved in platelet-leukocyte interactions requires that the identity of all the adhesive ligands be established. Therefore, we have evaluated the presence of intercellular adhesion molecules (ICAMs)' on the surface of resting and activated platelets. We present evidence that ICAM-2, and not ICAM-1 or ICAM-3, is present on the surface of resting and activated platelets. This 62-integrin ligand is constitutively expressed on platelets and has a molecular weight similar to that found previously on vascular endothelium and certain T cell lines (13). Furthermore, ICAM-2 on platelets is capable of supporting adhesion to purified leukocyte functionassociated antigen-i (LFA-1) and to LFA-1 on activated T lymphocytes. ICAM-2 is the first ligand for an integrin to be described on the platelet surface. Monoclonal antibodies. The following previously described murine mAbs to human antigens were used: RRl/1 (anti-ICAM-1, IgGl) (15), CBR-IC2/1 (anti-ICAM-2, IgG2a) (13), CBR-IC2/2 (anti-ICAM-2, IgG2a) (13), CBR-IC3/1 (anti-ICAM-3, IgGi) (16), TS1/ 22 (anti-CDlla, IgGl) (17) , and TS2/9 (anti-LFA-3, IgGl) (17) were produced in our laboratory. BI (anti-CD20, IgG2a) (18), MY4 (anti-CD 14, IgG2b) (19) , and T3 (anti-CD3, IgGi ) (20) treated with an equal volume of 2 x SDS-PAGE sample buffer, heated to 1000C for 2 min, and subjected to SDS 8% PAGE (27) . Proteins were visualized with intensifying screens for 3 d.
Labeling of proteins. Purified mAb to ICAM-2 was radioiodinated with Na1"'I (10 piCil/g mAb) using lodogen and stored in PBS at 40C (28) . The labeled mAb was used in quantitative binding studies within 2 wk.
Binding experiments. A direct solution-phase saturation assay was used to evaluate '25I-labeled anti-ICAM-2 binding to unfixed gel-filtered platelets. Resting or activated platelets (50 p1, 1.5-2.0 x 108 cells/ml) were incubated with 50 1Ld radiolabeled mAb at varying concentrations for 2 h at RT. The free and platelet-bound antibodies were separated by centrifugation through a 1:9 (vol/vol) Apiezon oil A/nbutyl phthalate mixture (29) and "25I-labeled ICAM-2 antibody binding was measured in a Beckman Gamma 8000 spectrometer (Beckman Instruments, Inc., Fullerton, CA). Nonspecific binding was determined in the presence of a 100-fold excess of unlabeled mAb and was subtracted from total binding to yield the specific binding. The number of binding sites per platelet was determined according to Scatchard (30) . Immunohistochemistry. Bone marrow smears, performed for evaluation of idiopathic thrombocytopenia, were obtained with the permission of The Children's Hospital (Boston, MA). They were air-dried and subsequently fixed for 90 s in acetone/methanol/40% formalin (19:19:2). The primary antibody, anti-ICAM-2, was used at dilutions of 1:50 to 1:500. Subsequent steps were performed using reagents from the Dako APAAP kit for mouse monoclonal antibodies (Dako Corp., Carpinteria, CA). The substrate solution contained levamisole to inhibit endogenous alkaline phosphatase. Smears were counter-stained in Gill's hematoxylin and mounted in aqueous medium. For electron microscopy, citrated blood was dripped into a beaker containing 90 ml of fixative (4% paraformaldehyde in McLean and Nakane's buffer [31] ) for 1 h.
The mixture was spun at 150 g for 20 min at 20°C (32) . The pellet was embedded in 2.1 M sucrose, frozen, and stored in liquid nitrogen. Frozen thin sections were cut as previously described (33) (34) (35) . The primary antibody, ICAM-2, was used at a dilution of 1:200, followed by rabbit anti-mouse Ig (Zymed Laboratories, Inc.) as a bridge ( 1:100).
This was followed by the gold label, protein A-10, obtained from the Department of Cell Biology, University of Utrecht (Utrecht, The Netherlands), at 1:50 dilution. The grids were then stained with uranyl acetate and embedded in methyl cellulose. A nonbinding control mAb was also tested.
Cell adhesion assays. Immunoaffinity purified LFA-1 (36) For the 96-well plate assays, platelets were resuspended in 2 ml of Hepes buffer containing 2 mM RGDS (Arg-Gly-Asp-Ser) (Peninsula Laboratories, Inc., Belmont, CA) and labeled with 10 ,g/ml of 2',7'-bis-(2-carboxyethyl)-5 (and-6) carboxyfluorescein (Molecular Probes, Inc., Eugene, OR) for 30 min at 37°C. After washing twice, the platelets were resuspended in Hepes buffer at a concentration of 2 x 108 cells/ ml. mAb pretreatment of the cells was performed as described above followed by the addition of 50 il of platelet suspension to the wells.
The plates were then briefly centrifuged (900 g, 3 min, 370C) and incubated at 370C for 30 min. The wells were washed six times by adding 200 MI of binding buffer and aspirating with a 23-gauge needle.
Fluorescence was directly quantitated from the 96-well plates using a Pandex fluorescence concentration analyzer (Baxter Healthcare Corp., Mundelein, IL).
Purification of T lymphocytes. Human PBMC were isolated from citrate-anticoagulated whole blood after dextran sedimentation and density separation over Ficoll-Hypaque (37) . Purified T lymphocytes were prepared from PBMC by negative selection using magnetic cell sorting, as described (38, 39) . Briefly, PBMC were resuspended to a concentration of 1 x 107/ml in PBS, 1% BSA, and 5 mM EDTA, pH 7.4 (PBE).
Then, the cells were incubated with a mixture of mAb (5 MSg/ml) capable of reacting with monocytes (MY4), B lymphocytes (B1), and natural killer cells (3G8) for 30 min on ice. After two washes in PBE, cells were incubated with magnetic microbeads conjugated to rat anti-mouse IgGI and IgG2a + 2b (MACS; Milteyni Biotec, Sunnyvale, CA) for 30 min on ice and then passed over a magnetic column. Immunofluorescence flow cytometry showed the purified T lymphocyte preparations to contain > 95% T lymphocytes (CD3+) and < 1% monocytes (CD14+), B lymphocytes (CD20+), or natural killer (CD16+) cells. The presence of platelets associated with lymphocytes was evaluated using mAb to CD41 and P-selectin and was undetectable. T lymphocytes purified in this manner had > 95% cell viability as determined by trypan blue exclusion and were used in assays within 6 h of purification. After isolation, the cells were stored in Hanks' balanced salt solution (HBSS; Gibco Laboratories, Grand Island, NY) supplemented with 10 mM Hepes, 1.0 mM MgCl2, and 5 mM EGTA, pH 7.4.
Platelet binding to glass slides. Glass slides (75 x 50 mm; Coming Glass Co., Coming, NY) were soaked over night in a chromic-sulfuric acid cleaning solution (Fisher Scientific, Fair Lawn, NJ) and then rinsed with distilled water for 4 h. The slides were dried with anhydrous acetone and immersed once in a 4% solution of 3-aminopropylthriethoxysilane (Sigma Immunochemicals) in acetone for 2 min (40) . Then, the slides were rinsed once with acetone, washed with distilled water, and dried for 2 h at 100"C.
Platelets were purified from the same donor as used in T cell isolation.
Briefly, platelet-rich plasma was centrifuged at 800 g for 5 min at 37°C and washed twice in Hepes buffer containing 1% HSA. The platelets were diluted to 5 x 108 cells/m-l in the same buffer, and 200 pl was aliquoted onto the surface of the glass slides. Platelets were allowed to settle for 30 min at 370C before rinsing and incubating the slides with buffer for 30 min at 370C to block nonspecific interactions. The platelets were then stimulated with 1 U/ml of human thrombin for 2 min before use in the flow chamber. A confluent layer of spread platelets was formed and confirmed by light microscopy for each experiment.
Detachment assays. A glass slide containing adherent platelets was assembled in a parallel-plate laminar flow chamber (260-pm gap thickness) in which a uniform wall shear stress is generated (8 
Results
Immunofluorescence flow cytometry ofplatelets. Flow cytometry showed that ICAM-2 but not ICAM-1 or ICAM-3 is expressed on the surface of platelets (Fig. 1, A-F buffer with 5% ,6-mercaptoethanol at 100°C and subjected to SDS 8% PAGE and radiography with enhancing screens. Molecular weight standards are shown in lane 1.
[ANTIBODY] (ug/ml) to the surface of platelets upon activation as described previously (Fig. 1 G) . ICAM-2 was expressed substantially higher, by about 1 log, than the immunoglobulin superfamily adhesion molecule, LFA-3 (CD58) (Fig. 1) . Surface expression of ICAM-2 was lower than gpIIbIIIa (CD41) and P-selectin on activated platelets (Fig. 1) . Unfixed resting and stimulated platelets gave similar results to fixed cells. Biochemical characterization ofICAM-2. Immunoprecipitation of ICAM-2 from '251-surface-labeled platelet lysates revealed that it was 59,000 Mr under reducing conditions (Fig.  2, lane 4) . ICAM-2 from platelets comigrated with ICAM-2 immunoprecipitated from the T lymphoblastoid cell line, SKW3 (Fig. 2, lane 3) . mAb to ICAM-1 failed to immunoprecipitate any labeled material from the platelet lysate (data not shown). Site density determination. Binding of '251-labeled ICAM-2 mAb to platelets was saturable (Fig. 3 ). Scatchard analysis (Fig. 3, inset) Immunocytochemistry. Expression of ICAMs on bone marrow cells was examined on smears stained with ICAM-1, ICAM-2, or ICAM-3 mAb and APAAP immunohistochemistry. At a 1:500 dilution of the ICAM-2 mAb (5.3 ag/ml), a brilliant red staining was observed for most megakaryocytes (Fig. 4 a) (Fig. 4 b) .
Subcellular localization of ICAM-2 was evaluated by using an immunogold procedure on frozen thin sections of resting platelets. Immunogold label was evident not only on the plasma membrane, but also along the membrane of the surface connected canalicular system (SCCS) (Fig. 5) . Other organelles were not labeled above background. When the control mAb X63 was used, labeling was rare (Fig. 5 B) . Functional characterization of ICAM-2 on platelets. Previous studies suggest that LFA-1 on leukocytes is capable of binding to a ligand on platelets. However, characterization of these interactions is complicated by the presence of multiple adhesion receptors on both cells. To determine if ICAM-2 expressed on the surface of platelets was capable of interacting with LFA-I, platelets were incubated in plates or microtiter wells coated with purified LFA-1. Platelets bind to purified LFA-I (Figs. 6, a and b, and 7) . Similar binding was seen in the presence of control mAb TPI / 15 (anti-CD3 1), in the absence of this mAb, or if mAb to ICAM-1 or ICAM-3 was preincubated with platelets (data not shown). This interaction was almost completely inhibited by mAbs to ICAM-2 or LFA-1 (Figs. 6, c and d, and 7 binding was inhibited by mAb to ICAM-2 and LFA-1. Inhibition by mAb to LFA-1 and ICAM-2 was equal, and mAb to ICAM-1 and ICAM-3 had no effect, suggesting that ICAM-2 is the only ligand on platelets recognized by LFA-1. All binding was abolished in the presence of EDTA demonstrating dependence on Mg2+. When unstimulated lymphocytes were allowed to settle on platelet-coated glass slides in the presence of Mg 2+ and Ca2+, a similar number of lymphocytes formed rolling adhesions as compared with the PMA-induced firm attachments described above; the former were abolished by treatment with mAb to P-selectin (data not shown).
Discussion
This study demonstrates that ICAM-2 is expressed on the surface of resting and thrombin-activated platelets. ICAM-2 is the only currently known cell-surface integrin ligand expressed on platelets. Activation of platelets resulted in no change in surface expression of ICAM-2 as determined by flow cytometry and saturation binding with mAb. The constitutive expression of this adhesion molecule on platelets is analogous to its constitutive expression on endothelium (13). This is in contrast to P-selectin, which is rapidly translocated to the surface of platelets upon activation. Immunohistochemistry and immunogold electron microscopy showed that ICAM-2 is expressed in bone marrow on megakaryocytes and in platelets is restricted to the plasma membrane and SCCS. ICAM-2 from platelets migrates as a band of 59,000 M, in SDS-PAGE under reducing conditions, identical to ICAM-2 isolated from the T cell line SKW3. The average number of ICAM-2 binding sites per platelet is 3,000. ICAM-2 expressed on platelets is functional, since it supports adhesion to purified and cellular LFA-1. This interaction is specifically inhibited by mAb to either ICAM-2 or LFA-1 and was Mg2' dependent.
ICAM-2 is the only ligand on platelets for LFA-1, as shown by equal inhibition by mAb to LFA-l and ICAM-2 of platelet binding to purified LFA-1 and of T lymphocyte binding to platelet monolayers. Furthermore, mAbs to ICAM-1 or ICAM-3 have no effect on either assay.
When lymphocytes adherent to platelets through the LFA-1 /ICAM-2 interaction were subjected to shear flow, they did not roll, showing that firm attachments had developed. Lymphocyte interaction with platelets through P-selectin is similar in binding efficiency in the same assay system, but permits rolling when the cells are subjected to shear flow (data not shown). Interaction with P-selectin requires Ca2' and does not require PMA ICAM-2 is a member of the immunoglobulin superfamily of adhesion molecules (42) . ICAM-2 is constitutively expressed at high levels on endothelial cells (13). On resting endothelial cells, its level is estimated to be 10-15-fold higher than the cytokine-inducible adhesion molecule, ICAM-1. ICAM-2 is the most prominent LFA-1 ligand on resting endothelia and a candidate for facilitating basal extravasation of lymphocytes and monocytes (13). The important interactions between f32-integrins and ICAM-l and ICAM-2 in adherence and subsequent transmigration of leukocytes across endothelial cells have been well characterized (43, 44) . ICAM-2 on platelets may serve a similar function. The adherence of platelets to damaged endothelium and subsequent rapid expression of P-selectin would result in the recruitment of leukocytes to such areas (45, 46 anion production (47, 48) . Thus, the interaction between LFA-1 and ICAM-2 may have significant clinical consequences in the facilitation of inflammatory and hemostatic processes at sites of vascular injury.
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